Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.
November 2, 2022

Consolidated Financial Results
for the First Six Months of the Fiscal Year Ending March 31, 2023
(Under Japanese GAAP)
Listed Company: Zeria Pharmaceutical Co., Ltd.
(Stock Exchange: Tokyo Stock Exchange)
Code Number: 4559
(URL: https://www.zeria.co.jp/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division
TEL (03) 3661-1039
Scheduled date to submit the Quarterly Securities Report: November 7, 2022
Scheduled date to commence dividend payments:
December 1, 2022
Preparation of supplementary documents to the quarterly financial results:
Yes
Holding of quarterly financial results presentation:
Yes (for analysts, institutional investors and the press)(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2022 through September 30, 2022)(1) Consolidated Financial Results (cumulative)(Percentage figures indicate changes from the same period of the previous year.)
Profit attributable toOperating profit
Ordinary profit
owners of parent

Net sales
Six months ended

Million yen%

Million yen%

Million yen%

Million yen%

September 30, 2022

33,712

17.9

5,894

120.6

5,182

66.3

3,998

89.0

September 30, 2021

28,606

12.1

2,672

67.2

3,116

138.4

2,115

52.4

Note: Comprehensive income: For the six months ended September 30, 2022: 8,069 million yen [267.7%]
For the six months ended September 30, 2021: 2,194 million yen [10.9%]

Basic earnings
per share

Diluted earnings
per share

Six months ended

Yen

Yen

September 30, 2022

90.41

–

September 30, 2021

46.65

–

(2) Consolidated Financial Position
Total assets
As of

Net assets

Equity ratio

Net assets per share

Million yen

Million yen%

Yen

September 30, 2022

134,40761,82245.8

1,395.01

March 31, 2022

124,282

55,09244.2

1,236.09

Reference: Equity: As of September 30, 2022: 61,581 million yen

As of March 31, 2022: 54,894 million yen

2. Dividends
Annual dividends
First quarter

Second quarter

Third quarter

Yen

Yen

Yen

Yen

Yen

Year ended
March 31, 2022

–

17.00

–

18.00

35.00

Year ending
March 31, 2023

–

18.00
–

18.00

36.00

Year ending
March 31, 2023 (Forecast)
Note: Revision of the forecast of dividends most recently announced: None

Year-endTotal

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2023 (April 1, 2022 through March 31, 2023)(Percentage figures indicate changes from the same period of the previous year.)
Basic
Profit attributable toOperating profit
Ordinary profit
earnings perowners of parent
share

Net sales

Full year

Million yen%

Million yen%

Million yen%

Million yen%

Yen

66,000

10.9

7,000

10.0

7,000

17.9

5,600

41.4

126.73

Note: Revision of the financial forecast most recently announced: None

* Notes(1) Changes in significant subsidiaries during the six months ended September 30, 2022 (changes in specified subsidiaries
resulting in changes in scope of consolidation): None
Inclusion: – (Company name: –)Exclusion: – (Company name: –)(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes
Note: For details, please refer to “2. Quarterly Consolidated Financial Statements and Significant Notes Thereto, (4) Notes to quarterly
consolidated financial statements” on page 10 of the Attached Material.

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after
error corrections
1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None
4) Restatement of prior period financial statements after error corrections: None
Note: For details, please refer to “2. Quarterly Consolidated Financial Statements and Significant Notes Thereto, (4) Notes to quarterly
consolidated financial statements” on page 10 of the Attached Material.

(4) Number of shares issued (common shares)
1) Number of shares issued as of the end of the term (including treasury shares):
As of September 30, 2022: 53,119,190 shares
As of March 31, 2022: 53,119,190 shares
2) Number of shares of treasury shares as of the end of the term:
As of September 30, 2022: 8,974,949 shares
As of March 31, 2022: 8,709,322 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
For the six months ended September 30, 2022: 44,229,546 shares
For the six months ended September 30, 2021: 45,360,392 shares* Quarterly Financial Results Are Exempt from Quarterly Review Conducted by Certified Public Accountants or an
Audit Corporation.
* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters
The description about the future including the projection in this document is based on information available to the Company
at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do notconstitute assurances regarding actual results by the Company. The actual results for future terms may differ from theinformation in this document due to various factors. For the assumptions made in financial forecasts and cautions concerning
the use thereof, please refer to “1. Qualitative Information on Quarterly Financial Results, (3) Explanation of consolidated
financial forecasts and other forward-looking statements” on page 4 of the Attached Material.

○Table of contents of attachments
1. Qualitative Information on Quarterly Financial Results ......................................................................................2(1) Explanation of operating results .................................................................................................................................. 2(2) Explanation of financial position ................................................................................................................................. 2(3) Explanation of consolidated financial forecasts and other forward-looking statements .......................................... 4
2. Quarterly Consolidated Financial Statements and Significant Notes Thereto .....................................................5(1) Quarterly consolidated balance sheet .......................................................................................................................... 5(2) Quarterly consolidated statement of income and quarterly consolidated statement of comprehensive income .... 7
Quarterly consolidated statement of income ..................................................................................................7
Quarterly consolidated statement of comprehensive income.........................................................................8(3) Quarterly consolidated statement of cash flows ......................................................................................................... 9(4) Notes to quarterly consolidated financial statements ...............................................................................................10(Notes on premise of a going concern) ........................................................................................................10(Notes on significant changes in the amount of shareholders’ equity) ........................................................10(Adoption of special accounting methods for preparation of quarterly consolidated financial statements) 10(Change in accounting policy) .....................................................................................................................10(Segment information, etc.) ......................................................................................................................... 11
3. Supplemental Information ..................................................................................................................................12(1) Sales results .................................................................................................................................................................12(2) Sales of major products and merchandise Consolidated ..........................................................................................13(3) Status of pipeline of new drugs ..................................................................................................................................14

1

1. Qualitative Information on Quarterly Financial Results(1) Explanation of operating results
Net sales for the first six months of the fiscal year ending March 31, 2023 were 33,712 million yen (up 17.9%
from the same period of the previous fiscal year). As for profits, operating profit was 5,894 million yen (up120.6% from the same period of the previous fiscal year), ordinary profit was 5,182 million yen (up 66.3%
from the same period of the previous fiscal year), and profit attributable to owners of parent was 3,998 million
yen (up 89.0% from the same period of the previous fiscal year). The large difference in the year-on-year
growth rate between operating profit and ordinary profit is because although the Company recorded foreignexchange gains in the previous fiscal year, a large amount of foreign exchange losses was recorded in thecurrent fiscal year as a result of the rapid appreciation of the Swiss franc.
Following are the results by business segment.
(i) Ethical Pharmaceuticals Business
As for our mainstay product, Asacol, a therapeutic agent for ulcerative colitis, growth in sales of Asacol
1600mg, a high-dose formulation only on sale in overseas markets, contributed to increased sales. Sales ofEntocort (domestic sales name: Zentacort), an inflammatory bowel disease (IBD) therapeutic agent, also
increased, as sales grew in the overseas market in various regions, including Canada, Northern Europe,and also Italy, where the Company established a local subsidiary in the previous year. In addition, sales of
DIFICLIR, a therapeutic agent for Clostridium difficile infections, achieved a significant sales growth as aresult of aggressive investment of sales resources in response to its recommendation as a first-line drug in
the European guidelines for the treatment of infectious diseases. With regard to Acofide and Ferinject, we
are working to build the market, particularly in medical institutions performing endoscopy, and thedomains of gastroenterology, and obstetrics and gynecology.
As a result, net sales in the business amounted to 21,505 million yen (up 19.5% from the same period of
the previous fiscal year).
(ii) Consumer Healthcare Business
As for the Hepalyse range, although it is still affected by the spread of COVID-19 infection and a sharp
decline in demand from inbound tourists, its sales significantly increased owing to the substantial increasein the sales of the pharmaceutical Hepalyse range, as well as the Hepalyse W range for convenience
stores. Sales of the Chondroitin range remained strong, due in part to aggressive advertising andpromotional investments. On the other hand, sales of the WithOne range of botanical laxative products
decreased due to the impact from competing products.
As a result, net sales in the business amounted to 12,131 million yen (up 15.2% from the same period of
the previous fiscal year).
(iii) Other
Net sales in this segment amounted to 75 million yen (up 1.1% from the same period of the previous fiscal
year), mainly due to insurance agency business and real estate lease revenue.
(2) Explanation of financial position(i) Assets, liabilities, and net assets
Total assets at the end of the second quarter of the fiscal year ending March 31, 2023 were 134,407
million yen, an increase of 10,125 million yen from the end of the previous fiscal year. Current assets
increased 7,099 million yen to 48,763 million yen from the end of the previous fiscal year, and noncurrent assets increased 3,025 million yen to 85,644 million yen from the end of the previous fiscal year.
Major changes in current assets included an increase of 3,589 million yen in cash and deposits, anincrease of 2,512 million yen in notes and accounts receivable - trade, and an increase of 1,080 million
2yen in inventories such as merchandise and finished goods. The changes in non-current assets were an
increase of 548 million yen in property, plant and equipment, an increase of 2,959 million yen in
intangible assets, and a decrease of 481 million yen in investments and other assets.
Total liabilities at the end of the quarter under review were 72,585 million yen, an increase of 3,395
million yen from the end of the previous fiscal year. Current liabilities increased 3,736 million yen to47,929 million yen from the end of the previous fiscal year, and non-current liabilities decreased 340
million yen to 24,656 million yen from the end of the previous fiscal year. Main changes in current
liabilities were an increase of 2,727 million yen in short-term borrowings and an increase of 835 million
yen in income taxes payable. Main changes in non-current liabilities were a decrease of 905 million yen in
long-term borrowings, an increase of 319 million yen in provision for loss on cancellation of contracts,
and an increase of 264 million yen in other non-current liabilities including an increase in deferred tax
liabilities.
Net assets at the end of the quarter under review were 61,822 million yen, an increase of 6,729 million
yen from the end of the previous fiscal year. This was mainly due to profit attributable to owners of parentof 3,998 million yen, payment of 799 million yen as dividends declared at the end of the previous period,
an increase of 536 million yen in treasury shares, and an increase of 4,438 million yen in foreign currencytranslation adjustment.
As a result, equity ratio at the end of the quarter under review increased by 1.6% from the end of theprevious fiscal year to 45.8%.
(ii) Status of cash flows
Cash and cash equivalents (below, “cash”) at the end of the quarter under review increased 3,589 million
yen from the beginning of the period to 15,168 million yen. This was mainly due to net cash provided byoperating activities of 5,332 million yen, despite net cash used in investing activities of 963 million yen
and net cash used in financing activities of 2,119 million yen.
The status of each cash flow and its factors for the first six months of the current fiscal year are as follows.
[Net cash provided by (used in) operating activities]
Net cash provided by operating activities amounted to 5,332 million yen in the first six months of thecurrent fiscal year (up 2,220 million yen from the same period of the previous fiscal year). This was due
to factors including profit before income taxes of 4,970 million yen, depreciation of 2,466 million yen, adecrease in provision for bonuses of 514 million yen, an increase in trade receivables of 1,289 million
yen, and an increase in inventories of 409 million yen.
[Net cash provided by (used in) investing activities]
Net cash used in investing activities totaled 963 million yen in the first six months of the current fiscal
year (up 733 million yen from the same period of the previous fiscal year). This was mainly due to an
expenditure of 908 million yen for the purchase of property, plant and equipment.
[Net cash provided by (used in) financing activities]
Net cash used in financing activities totaled 2,119 million yen in the first six months of the current fiscal
year (down 1,037 million yen from the same period of the previous fiscal year). This was mainly due to anincrease of 1,873 million yen in short-term borrowings, proceeds from long-term borrowings of 500
million yen, repayments of long-term borrowings of 3,028 million yen, purchase of treasury shares of 538
million yen, and dividends paid of 798 million yen.

3

(3) Explanation of consolidated financial forecasts and other forward-looking statements
The consolidated financial forecast for the fiscal year ending March 31, 2023 remains unchanged from theconsolidated financial forecast announced on May 11, 2022. For details, please refer to “Notice Regarding
Revisions to Financial Forecasts,” announced on October 31, 2022 (Japanese version only).

42. Quarterly Consolidated Financial Statements and Significant Notes Thereto(1) Quarterly consolidated balance sheet(Thousands of yen)
As of March 31, 2022
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable - trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings, net
Land
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Sales right
Other
Total intangible assets
Investments and other assets
Investment securities
Retirement benefit asset
Other
Allowance for doubtful accounts
Total investments and other assets
Total non-current assets
Total assets
Liabilities
Current liabilities
Accounts payable - trade
Short-term borrowings
Income taxes payable
Provision for bonuses
Other
Total current liabilities
Non-current liabilities
Long-term borrowings
Provision for loss on cancellation of contracts
Retirement benefit liability
Asset retirement obligations
Other
Total non-current liabilities
Total liabilities

5

As of September 30, 2022

11,704,282
16,206,812
6,721,583
1,409,684
3,819,276
1,855,502(53,425)
41,663,717

15,293,974
18,719,715
7,314,567
1,194,974
4,521,242
1,791,257(72,368)
48,763,363

6,655,232
12,354,010
4,130,101
23,139,343

6,499,554
12,361,492
4,826,460
23,687,508

5,830,459
27,539,473
7,836,095
41,206,029

5,702,690
29,621,682
8,841,092
44,165,464

7,005,587
10,736,005
583,595(51,945)
18,273,242
82,618,615
124,282,333

6,681,999
10,591,887
564,753(47,230)
17,791,409
85,644,382
134,407,745

2,049,590
33,842,933
458,297
1,530,935
6,311,307
44,193,063

2,425,768
36,570,603
1,293,577
1,068,358
6,570,900
47,929,209

18,385,860
490,142
1,073,819
55,827
4,991,146
24,996,794
69,189,858

17,480,830
809,440
1,054,164
55,9295,255,834
24,656,199
72,585,408

(Thousands of yen)
As of March 31, 2022
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders’ equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets

6

As of September 30, 2022

6,593,398
11,685,121
48,860,697(17,593,074)
49,546,143

6,593,398
11,685,121
52,059,900(18,129,863)
52,208,557(193,416)
3,215,379
2,326,536
5,348,499
197,832
55,092,474
124,282,333(458,313)
7,653,742
2,177,596
9,373,025
240,754
61,822,336
134,407,745

(2) Quarterly consolidated statement of income and quarterly consolidated statement of comprehensive
incomeQuarterly consolidated statement of income(Thousands of yen)Six months ended
September 30, 2021
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit
Non-operating income
Interest income
Dividend income
Foreign exchange gains
Other
Total non-operating income
Non-operating expenses
Interest expenses
Foreign exchange losses
Other
Total non-operating expenses
Ordinary profit
Extraordinary income
Gain on sale of non-current assets
Gain on sale of investment securities
Total extraordinary income
Extraordinary losses
Loss on retirement of non-current assets
Provision for loss on cancellation of contracts
Total extraordinary losses
Profit before income taxes
Income taxes
ProfitProfit attributable to non-controlling interests
Profit attributable to owners of parent

7

Six months ended
September 30, 2022

28,606,173
8,462,724
20,143,448
17,470,923
2,672,525

33,712,480
9,376,722
24,335,758
18,441,079
5,894,678

6,759
148,091
417,551
36,809609,211

26,461
158,136–
45,555230,153

148,520–
16,479165,000
3,116,736

181,259
748,121
13,205942,586
5,182,245

3,470
3,367
6,837

260
19,94020,200

3,995
–
3,995
3,119,578
998,954
2,120,624
4,632
2,115,992

3,350
228,300
231,651
4,970,794
964,014
4,006,779
8,199
3,998,580

Quarterly consolidated statement of comprehensive income(Thousands of yen)Six months ended
September 30, 2021
ProfitOther comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Remeasurements of defined benefit plans, net of tax
Total other comprehensive income
Comprehensive income
Comprehensive income attributable toComprehensive income attributable to owners of parent
Comprehensive income attributable to non-controllinginterests

8

Six months ended
September 30, 2022

2,120,624

4,006,779(320,290)
720,862(326,784)
73,7872,194,411(264,896)
4,476,703(148,940)
4,062,866
8,069,646

2,177,573

8,023,106

16,83846,539(3) Quarterly consolidated statement of cash flows(Thousands of yen)Six months ended
September 30, 2021
Cash flows from operating activities
Profit before income taxes
Depreciation
Amortization of goodwill
Increase (decrease) in provision for bonuses
Increase (decrease) in provision for loss on cancellationof contracts
Increase (decrease) in retirement benefit liability
Interest and dividend income
Interest expenses
Decrease (increase) in trade receivables
Decrease (increase) in inventories
Increase (decrease) in trade payables
Decrease (increase) in other current assets
Increase (decrease) in other current liabilities
Decrease (increase) in retirement benefit asset
Other, net
SubtotalInterest and dividends received
Interest paid
Income taxes paid
Net cash provided by (used in) operating activities
Cash flows from investing activities
Purchase of property, plant and equipment
Purchase of intangible assets
Purchase of investment securities
Proceeds from sale of investment securities
Other, net
Net cash provided by (used in) investing activities
Cash flows from financing activities
Net increase (decrease) in short-term borrowings
Proceeds from long-term borrowings
Repayments of long-term borrowings
Repayments of lease liabilities
Purchase of treasury shares
Dividends paid
Dividends paid to non-controlling interests
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash
equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Increase (decrease) in cash and cash equivalents resulting
from change in scope of consolidation
Cash and cash equivalents at end of period

9

Six months ended
September 30, 2022

3,119,578
2,321,125
349,467(305,242)

4,970,794
2,466,358
354,879(514,895)(28,302)228,300

110,409(154,850)
148,520(1,734,982)(762,273)
143,623
932,126(392,234)(334,602)(12,593)3,399,768
154,854(140,890)(302,270)
3,111,463

109,324(184,597)
181,259(1,289,682)(409,623)
193,809(164,194)
215,451(354,809)(117,947)
5,684,428
184,616(180,360)(356,493)
5,332,190(361,126)(214,326)(1,164,456)
37,186
5,941(1,696,780)(908,651)(156,032)(132,488)
215,908
17,787(963,476)(7,310,442)
10,009,350(1,649,550)(111,162)(1,243,504)(773,214)(3,513)(1,082,036)

1,873,266
500,000(3,028,710)(123,158)(538,398)(798,347)(3,929)(2,119,276)

143,687

1,340,254

476,334
9,668,938

3,589,691
11,579,282

129,430–

10,274,703

15,168,974

(4) Notes to quarterly consolidated financial statements(Notes on premise of a going concern)
Not applicable.
(Notes on significant changes in the amount of shareholders’ equity)
Not applicable.
(Adoption of special accounting methods for preparation of quarterly consolidated financial statements)
Calculation of tax expenses
Tax expenses were calculated by reasonably estimating the effective tax rate after applying tax effectaccounting to the profit before income taxes for the fiscal year that includes the second quarter of the current
fiscal year and multiplying profit before income taxes by such estimated effective tax rate.
(Change in accounting policy)
Adoption of the Implementation Guidance on Accounting Standard for Fair Value Measurement
The Company adopted the Implementation Guidance on Accounting Standard for Fair Value Measurement(ASBJ Guidance No. 31, June 17, 2021) from the beginning of the first quarter of the current fiscal year. In
accordance with the transitional treatment prescribed in paragraph 27-2 of the Implementation Guidance on
Accounting Standard for Fair Value Measurement, the new accounting policies prescribed by the
Implementation Guidance on Accounting Standard for Fair Value Measurement are to be applied
prospectively. There is no impact on the consolidated quarterly financial statements for the first six months ofthe current fiscal year.

10

(Segment information, etc.)[Segment information]
Ⅰ First six months of the previous fiscal year (from April 1, 2021 to September 30, 2021)
1. Information on net sales and profit or loss by reportable segment(Thousands of yen)

Adjustment(Note 2)

Amountrecorded inquarterly
consolidated
statement ofincome(Note 3)28,606,173–

28,606,173

284,004

284,053(284,053)–

28,531,348

358,878

28,890,226(284,053)

28,606,173

5,058,667

128,480

5,187,147(2,514,621)

2,672,525

Reportable segment
Other(Note 1)

EthicalPharmaceuticals
Business

Consumer
Healthcare
Business

Total

17,997,949

10,533,349

28,531,299

74,873–48

48

17,997,949

10,533,398

3,081,706

1,976,960

Total

Net sales
Sales to externalcustomers
Intersegment
sales and transfers
Total
Segment profit(Notes) 1. “Other” is a business segment not included in the reportable segments and includes the insurance agency businessand real estate business.
2. Adjustment of segment profit of (2,514,621) thousand yen is mainly corporate expenses such as general andadministrative expenses that are not allocated to reportable segments.
3. Segment profit is adjusted with operating profit in the quarterly consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment
Not applicable.
Ⅱ First six months of the current fiscal year (from April 1, 2022 to September 30, 2022)
1. Information on net sales and profit or loss by reportable segment(Thousands of yen)

Adjustment(Note 2)

Amountrecorded inquarterly
consolidated
statement ofincome(Note 3)33,712,480–

33,712,480

219,681

222,434(222,434)–

33,639,517

295,398

33,934,915(222,434)

33,712,480

8,322,853

116,456

8,439,309(2,544,631)

5,894,678

Reportable segment

Net sales
Sales to externalcustomers
Intersegment
sales and transfers
Total
Segment profit

Other(Note 1)

EthicalPharmaceuticals
Business

Consumer
Healthcare
Business

Total

21,505,406

12,131,357

33,636,763

75,716

2,694

58

2,753

21,508,101

12,131,416

5,867,879

2,454,974

Total(Notes) 1. “Other” is a business segment not included in the reportable segments and includes the insurance agency businessand real estate business.
2. Adjustment of segment profit of (2,544,631) thousand yen is mainly corporate expenses such as general andadministrative expenses that are not allocated to reportable segments.
3. Segment profit is adjusted with operating profit in the quarterly consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment
Not applicable.

113. Supplemental Information(1) Sales results
The table below shows sales results by business segment in the first six months of the current fiscal year.
(Thousands of yen)First six months ofthe current fiscal year

Name of segment(from April 1, 2022
to September 30, 2022)

Increase/(decrease) overthe same periodof the previous fiscal year (%)

Ethical Pharmaceuticals Business

21,505,406

19.5

Consumer Healthcare Business

12,131,357

15.2

33,636,763

17.9

75,716

1.1

33,712,480

17.9

Total reportable segment
Other
Total
(Note)

Inter-segment transactions are offset and eliminated.

12

(2) Sales of major products and merchandise Consolidated(Thousands of yen)

1. Ethical Pharmaceuticals BusinessFirst six months ofFirst six months ofthe previous fiscal year

the current fiscal year

Percentage change(from April 1, 2021

(from April 1, 2022(%)

to September 30, 2021)

to September 30, 2022)

17,997,949

21,505,406

19.5

Asacol8,506,104

9,881,146

16.2

DIFICLIR

2,279,800

3,895,442

70.9

Entocort

2,245,177

2,935,555

30.7

Acofide1,580,552

1,541,840

(2.4)

Other

3,386,314

3,251,421(4.0)

10,533,349

12,131,357

15.2

Hepalyse range

3,237,728

4,698,724

45.1

Chondroitin range

2,595,823

2,634,015

1.5

WithOne range

647,510

620,943(4.1)

4,052,288

4,177,673

3.1

74,87375,716

1.1

28,606,173

33,712,480

17.9

2. Consumer Healthcare Business

Other
3. Other Business
Total

13

(3) Status of pipeline of new drugs
I.

Domestic

As of November 2, 2022

Stage

Development Code/
Generic Name

Development

Indications

Classification

OriginPhase IIIZ-338/Acotiamide

Zeria

Pediatric functional
dyspepsia

Upper gastrointestinal
motility modulator

Original

Phase III

ZG-801/Patiromer
Sorbitex Calcium

Zeria

Hyperkalemia

Potassium binder

In-licensed

Phase II*
(InvestigatorInitiated Trial)

Z-338/Acotiamide

KyushuUniversity

Esophagogastricjunction outflow
obstruction

Upper gastrointestinal
motility modulator

Original*: Supported by a grant from Japan Agency for Medical Research and Development (AMED)II. Overseas
Stage

Development Code/
Generic Name

Development

Indications

Classification

OriginPhase III(Europe)

Z-338/Acotiamide

Zeria

Functional
dyspepsia

Upper gastrointestinal
motility modulator

Original

NDA approved(Mexico, Honduras)

Z-338/Acotiamide

Faes Farma

Functional
dyspepsia

Upper gastrointestinal
motility modulator

Original (Outlicensed)

NDA filed (Chile,
Colombia, Peru,
Ecuador, Dominican
Republic, Costa
Rica, Guatemala,Panama)Z-338/Acotiamide

Faes Farma

Functional
dyspepsia

Upper gastrointestinal
motility modulator

Original (Outlicensed)

NDA filed(Thailand,
Indonesia)

Z-338/Acotiamide

Meiji Seika
PharmaFunctional
dyspepsia

Upper gastrointestinal
motility modulator

Original (Outlicensed)

14